EP3843761A4 - Chimeric oncolytic herpesvirus that stimulate an antitumor immune response - Google Patents
Chimeric oncolytic herpesvirus that stimulate an antitumor immune response Download PDFInfo
- Publication number
- EP3843761A4 EP3843761A4 EP19855584.9A EP19855584A EP3843761A4 EP 3843761 A4 EP3843761 A4 EP 3843761A4 EP 19855584 A EP19855584 A EP 19855584A EP 3843761 A4 EP3843761 A4 EP 3843761A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- stimulate
- immune response
- antitumor immune
- chimeric oncolytic
- oncolytic herpesvirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862725809P | 2018-08-31 | 2018-08-31 | |
PCT/US2019/049047 WO2020047398A1 (en) | 2018-08-31 | 2019-08-30 | Chimeric oncolytic herpesvirus that stimulate an antitumor immune response |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3843761A1 EP3843761A1 (en) | 2021-07-07 |
EP3843761A4 true EP3843761A4 (en) | 2022-06-08 |
Family
ID=69643794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19855584.9A Pending EP3843761A4 (en) | 2018-08-31 | 2019-08-30 | Chimeric oncolytic herpesvirus that stimulate an antitumor immune response |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3843761A4 (en) |
JP (2) | JP2021534786A (en) |
KR (1) | KR20210053923A (en) |
CN (1) | CN113396217A (en) |
AU (1) | AU2019333181A1 (en) |
BR (1) | BR112021003807A8 (en) |
CA (1) | CA3110406A1 (en) |
IL (1) | IL281085A (en) |
SG (1) | SG11202101829UA (en) |
WO (1) | WO2020047398A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023096996A2 (en) | 2021-11-24 | 2023-06-01 | Research Institute At Nationwide Children's Hospital | Chimeric hsv expressing hil21 to boost anti-tumor immune activity |
WO2023235377A1 (en) * | 2022-05-31 | 2023-12-07 | The Research Institute At Nationwide Children's Hospital | Il-27 expressing oncolytic viruses |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
WO2007005876A2 (en) * | 2005-07-01 | 2007-01-11 | The Uab Research Foundation | Chimeric herpes viruses and uses thereof |
-
2019
- 2019-08-30 WO PCT/US2019/049047 patent/WO2020047398A1/en unknown
- 2019-08-30 CA CA3110406A patent/CA3110406A1/en active Pending
- 2019-08-30 JP JP2021510715A patent/JP2021534786A/en active Pending
- 2019-08-30 EP EP19855584.9A patent/EP3843761A4/en active Pending
- 2019-08-30 CN CN201980072185.8A patent/CN113396217A/en active Pending
- 2019-08-30 SG SG11202101829UA patent/SG11202101829UA/en unknown
- 2019-08-30 KR KR1020217009134A patent/KR20210053923A/en active Search and Examination
- 2019-08-30 AU AU2019333181A patent/AU2019333181A1/en active Pending
- 2019-08-30 BR BR112021003807A patent/BR112021003807A8/en unknown
-
2021
- 2021-02-24 IL IL281085A patent/IL281085A/en unknown
-
2024
- 2024-05-10 JP JP2024077016A patent/JP2024102299A/en active Pending
Non-Patent Citations (3)
Title |
---|
GHONIME MOHAMMED G ET AL: "Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 9, no. 10, 26 August 2021 (2021-08-26), pages e002939, XP055915209, Retrieved from the Internet <URL:https://jitc.bmj.com/content/jitc/9/10/e002939.full.pdf?with-ds=yes> DOI: 10.1136/jitc-2021-002939 * |
GHONIME MOHAMMED G. ET AL: "Chimeric HCMV/HSV-1 and [Delta][gamma]134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory", TRANSLATIONAL ONCOLOGY, vol. 11, no. 1, 1 February 2018 (2018-02-01), United States, pages 86 - 93, XP055915040, ISSN: 1936-5233, DOI: 10.1016/j.tranon.2017.10.005 * |
See also references of WO2020047398A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2020047398A1 (en) | 2020-03-05 |
CN113396217A (en) | 2021-09-14 |
EP3843761A1 (en) | 2021-07-07 |
WO2020047398A9 (en) | 2020-04-30 |
BR112021003807A8 (en) | 2022-04-19 |
KR20210053923A (en) | 2021-05-12 |
BR112021003807A2 (en) | 2021-05-18 |
JP2021534786A (en) | 2021-12-16 |
IL281085A (en) | 2021-04-29 |
SG11202101829UA (en) | 2021-03-30 |
CA3110406A1 (en) | 2020-03-05 |
AU2019333181A1 (en) | 2021-03-18 |
JP2024102299A (en) | 2024-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3596118A4 (en) | Methods for modulating an immune response | |
EP3405190A4 (en) | Methods for inducing an immune response | |
EP3289083A4 (en) | Nucleoside-modified rna for inducing an adaptive immune response | |
EP3697592A4 (en) | 3d printer | |
EP3283110A4 (en) | Antibodies directed against interleukin 36 receptor (il-36r) | |
EP3756996A4 (en) | Flying object | |
EP3842529A4 (en) | Exosome-based antitumor vaccine | |
EP3529914A4 (en) | Uplink reference signal | |
EP3422867A4 (en) | Direct-fed microbials | |
EP3596610A4 (en) | Cooking system | |
EP3946448A4 (en) | Semi-synthetic biopolymers for use in stimulating the immune system | |
EP3585409A4 (en) | Csf1r-based chimeric proteins | |
EP4003535A4 (en) | Prebiotic-induced anti-tumor immunity | |
EP3664576A4 (en) | Heater | |
IL281085A (en) | Chimeric oncolytic herpesvirus that stimulate an antitumor immune response | |
EP3752163A4 (en) | Promoting immune responses | |
EP3612371A4 (en) | 3d printer and build module | |
EP3904773A4 (en) | Heating system | |
EP3710007A4 (en) | Use of imidazopyrimidine for modulating human immune response | |
EP3585410A4 (en) | Vsig8-based chimeric proteins | |
EP3894182A4 (en) | 3d printer | |
EP3774294A4 (en) | 3d printing system | |
EP3779285A4 (en) | Heating system | |
EP3814110A4 (en) | 3d printing control | |
EP3522721A4 (en) | Oven system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20210308 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220506 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/02 20060101ALI20220429BHEP Ipc: A61P 35/04 20060101ALI20220429BHEP Ipc: C12N 15/00 20060101ALI20220429BHEP Ipc: C12N 7/01 20060101ALI20220429BHEP Ipc: A61K 35/76 20150101AFI20220429BHEP |